The short version of Agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
=== 2. Supracrestal connective tissue === The supracrestal connective tissue comprises collagen fiber systems that contribute to the stability of the gingival attachment. During clinical attachment loss, these fibers undergo enzymatic degradation mediated by host inflammatory responses. Loss of this connective tissue attachment disrupts the physiologic gingival seal, facilitating subgingival biofilm colonization and promoting apical extension of the inflammatory lesion.
A review of four studies on the effectiveness of mindfulness-based cognitive therapy (MBCT), a recently developed class-based program designed to prevent relapse, suggests that MBCT may have an additive effect when provided with the usual care in patients who have had three or more depressive episodes, although the usual care did not include antidepressant treatment or any psychotherapy, and the improvement observed may have reflected non-specific or placebo effects. Of note, although Mindfulness-based cognitive therapy for depression prevented relapse of future depressive episodes, there is no research on whether it can cause the remission of a current depressive episode. Interpersonal psychotherapy (IPT) focuses on the social and interpersonal triggers that may cause depression. There is evidence that it is an effective treatment for depression. Here, the therapy takes a fairly structured course (often 12 sessions, as in the original research versions) as in the case with CBT; however, the focus is on relationships with others. Unlike family therapy, IPT is an individual format, so it is possible to work on interpersonal themes even if other family members do not come to the session. Therapy can be used to help a person develop or improve interpersonal skills in order to allow him or her to communicate more effectively and reduce stress. In a meta-analysis of 16 studies and 4,356 patients, the average improvement in depressive symptoms was an effect size of d = 0.63 (95% CI, 0.36 to 0.90).
After an oil drilling operation in 1903 in Dexter, Kansas produced a gas geyser that would not burn, Kansas geologist Erasmus Haworth collected samples of the escaping gas and took them back to the University of Kansas at Lawrence where, with the help of chemists Hamilton Cady and David McFarland, he discovered that the gas consisted of, by volume, 72% nitrogen, 15% methane (a combustible percentage only with sufficient oxygen), 1% hydrogen, and 12% an unidentifiable gas. With further analysis, Cady and McFarland discovered that 1.84% of the gas sample was helium. This showed that despite its overall rarity on Earth, helium was concentrated in large quantities under the American Great Plains, available for extraction as a byproduct of natural gas.Following a suggestion by Sir Richard Threlfall, the United States Navy sponsored three small experimental helium plants during World War I. The goal was to supply barrage balloons with the non-flammable, lighter-than-air gas. A total of 5,700 m3 (200,000 ft3) of 92% helium was produced in the program even though less than a cubic meter of the gas had previously been obtained. Some of this gas was used in the world's first helium-filled airship, the U.S. Navy's C-class blimp C-7, which flew its maiden voyage from Hampton Roads, Virginia, to Bolling Field in Washington, D.C., on December 1, 1921, nearly two years before the Navy's first rigid helium-filled airship, the Naval Aircraft Factory-built USS Shenandoah, flew in September 1923.
An enzyme-linked immunosorbent assay (ELISA) is one of the most common ways for detecting anti-U1 RNP antibodies in patient sera. In this procedure, purified or recombinant U1-RNP antigens are placed into microplate wells. After nonspecific binding sites are blocked, diluted patient serum is added to the wells and incubated. If specific autoantibodies are present, they can bind to the immobilized antigen. A secondary enzyme-conjugated anti-human IgG antibody is added, that it is followed by a substrate that produces a color change. This is read by spectrophotometry and compared to a standard curve to measure the levels of antibodies. Reference ranges are specific to each laboratory, and results must be interpreted in the context of clinical findings. This method is highly sensitive and frequently used to support diagnosis in patients with suspected MCTD or other connective tissue diseases. Other laboratory techniques include immunoblotting, immunoprecipitation, and multiplex immunoassays. Immunoblotting identifies antibodies directed against specific proteins within the U1 snRNP complex, while immunoprecipitation has traditionally been considered one of the most specific methods for confirming anti-U1 RNP antibodies. Multiplex immunoassays allow laboratories to detect several extracellular nuclear antigen antibodies at the same time, making them useful for evaluating those with suspected autoimmune diseases.
Sources: en.wikipedia.org
Both Takin' It to the Streets and Livin' on the Fault Line reflected Johnston's diminished role in the group following his illness. Restored to fitness and briefly back in the fold, he contributed one original song to Takin' It to the Streets ("Turn It Loose"), and also sang a verse on Simmons' tune "Wheels of Fortune". He also made live appearances with the band in 1976 (documented in a concert filmed that year at the Winterland in San Francisco, excerpts of which appear occasionally on VH1 Classic) but was sidelined once again that fall due to exhaustion. The Doobie Brothers recorded five new Johnston compositions for Livin' on the Fault Line, but Johnston decided the band's direction had strayed too far from their original sound. He left the band he co-founded, withdrew permission for the Doobie Brothers to use the five songs he contributed to Livin' on the Fault Line, and embarked on a solo career that eventually yielded one modestly successful 1979 Warner Brothers album, Everything You've Heard is True, which featured the single "Savannah Nights", and the less successful album Still Feels Good in 1981. Regardless, he received credit for guitars and vocals on Livin' on the Fault Line and was pictured on the album's inner sleeve band photo. During this period of transition, the band also elevated former roadie Bobby LaKind to onstage backup vocalist and percussionist. In the studio, LaKind first contributed percussion to Takin' It to the Streets but had been a member of the band's lighting crew since 1974.
== Microscopic appearance == Melanin is brown, non-refractile, and finely granular, with individual granules having a diameter of less than 800 nanometers. This differentiates melanin from common blood breakdown pigments, which are larger, chunky, and refractile, and range in color from green to yellow or red-brown. In heavily pigmented lesions, dense aggregates of melanin can obscure histologic detail. A dilute solution of potassium permanganate is an effective melanin bleach.
Kardashev first outlined his scale in a paper presented at the 1964 conference that communicated findings on BS-29-76, the Byurakan Conference in the Armenian SSR, which reviewed the Soviet radio astronomy space listening program. The paper was titled "Передача информации внеземными цивилизациями" or Transmission of Information by Extraterrestrial Civilizations. The paper was published in 1964 first in Russian in the March–April issue of the Astronomicheskii Zhurnal, then in English in the September–October 1964 issue of the Soviet Astronomical Journal. In it, the scientist presents a calculation of the evolution of the power needs of humanity. Assuming that overall human power use will continue to increase, he calculates that the rate of energy consumption will cross specific mileposts. Kardashev proposed a typology of technological civilizations based on the evolutive attainment of the three power harnessing mileposts he described. A civilization known as "Type I" has achieved a technological level close to the one attained on Earth at the time Kardashev's article was submitted (December 1963), with a rate of energy consumption evaluated at about 4×1012 watts (W). A civilization known as "Type II" would surpass the first by fourteen orders of magnitude, matching the entire power emitted by the Sun in about 3,200 years, i.e., Earth's home star's "output" at that time, predicted at 4×1026 W.
The Washington Post also followed up with a correction of errors in its earlier report on the Smithsonian acquisition, stating that it incorrectly referred to Ayyadurai as the inventor of electronic messaging; the 'bcc', 'cc', 'to' and 'from' fields existed previously; Ayyadurai had not been honored as the "inventor of email". Writing for Gizmodo, Sam Biddle argued that email was developed a decade before EMAIL, beginning with Ray Tomlinson's sending the first text letter between two ARPANET-connected computers in 1971. Biddle quoted Tomlinson: "[We] had most of the headers needed to deliver the message (to:, cc:, etc.) as well as identifying the sender (from:) and when the message was sent (date:) and what the message was about." Biddle allowed for the possibility that Ayyadurai may have coined the term "EMAIL" and used the header terms without being aware of earlier work, but maintained that the historical record isn't definitive on either point. Biddle wrote that "laying claim to the name of a product that's the generic term for a universal technology gives you acres of weasel room.
Chasmoendolith Colonizes fissures and cracks in the rock connected to the surface (chasm = cleft) Cryptoendolith Colonizes structural cavities within natural pore spaces within the rocks. These pores are usually indirectly connected to the rock surface; (crypto = hidden) Euendolith Penetrates actively into the interior of rocks forming channels and grooves that conform with the shape of its body, rock boring organism (eu = true) Hypoendolith Colonizes the pore spaces located on the underside of the rock and that make contact with the soil (hypo = under) Autoendolith Capable of rocks formation by mineral depositation (auto = self)
Sources: en.wikipedia.org
DNA turnover Any mechanism by which DNA sequences are exchanged non-reciprocally (e.g. via gene conversion, transposition, or unequal crossing-over) that causes continual fluctuations in the copy number of DNA motifs during an organism's lifetime. Such mechanisms are often major drivers of speciation between populations.
The group takes its name from Mighei (Ukraine), but the most famous member is the extensively studied Murchison meteorite. Many falls of this type have been observed and CM chondrites are known to contain a rich mix of complex organic compounds such as amino-acids and purine/pyrimidine nucleobases. CM chondrite famous falls:
Since u needs to be finite at r = 0, c1 = 0. The no slip boundary condition at the pipe wall requires that u = 0 at r = R (radius of the pipe), which yields c2 = GR2/4μ. Thus we have finally the following parabolic velocity profile:
Pro-inflammatory myeloid cells along with production of the pro-inflammatory cytokines interleukin-1α (IL-1α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α) have been found to increase with age in rodents and humans. This is part of "inflammaging". Activation of these myeloid cells and consequent elevation in cytokine levels have been found to be suppressed by thymulin via inhibition of NF-κB signaling. Thymulin levels decrease with age.
Dakin's solution is a dilute solution of sodium hypochlorite (0.4% to 0.5%) and other stabilizing ingredients, traditionally used as an antiseptic, e.g. to cleanse wounds in order to prevent infection. The preparation was for a time called also Carrel–Dakin solution or Carrel–Dakin fluid.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.